Experiences of levosimendan as an inotropic agent in conjunction with passive containment surgery

被引:3
作者
Bredin, Fredrik [1 ]
Franco-Cereceda, Anders
机构
[1] Karolinska Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
关键词
cardiomyopathy; heart failure surgery; hemodynamics;
D O I
10.1080/14017430601137160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Levosimendan is a calcium sensitizer with a positive inotropic effect without increasing oxygen consumption. We have evaluated the immediate effects of levosimendan on cardiac index when given peri-operatively to patients with dilated cardiomyopathy in conjunction with passive containment surgery. Design. Ten patients with dilated cardiomyopathy undergoing passive containment surgery with the ACORN Cardiac Support Device, either as the sole procedure or in combination with other open heart surgery, were after anaesthesia induction given levosimendan as a bolus dose of 12 mu g/kg followed by an infusion of 0.1 mu g/kg/min for 24 hours. Cardiac index were measured before extra corporal circulation, immediately after extra corporal circulation, at arrival to the intensive care unit and on post operative day 1. The need for inotropic support was recorded. Results. Nine of ten patients were preoperatively in a low cardiac output situation. At postoperative day 1 there was a significant increase in cardiac index from 2.1 +/- 0.1 to 2.8 +/- 0.2. Conclusions. This study confirms the theoretical benefits of levosimendan judged by an immediate significant positive effect on cardiac index.
引用
收藏
页码:197 / 200
页数:4
相关论文
共 10 条
[1]   Levosimendan [J].
Figgitt, DP ;
Gillies, PS ;
Goa, KL .
DRUGS, 2001, 61 (05) :613-627
[2]   Early results with cardiac support device implant in patients with ischemic and non-ischemic cardiomyopathy [J].
Franco-Cereceda, A ;
Lockwandt, U ;
Olsson, A ;
Bredin, F ;
Forssell, G ;
Öwall, A ;
Runsiö, M ;
Liska, J .
SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2004, 38 (03) :159-163
[3]   Heart failure overview [J].
Hunt, S .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (05) :1245-1246
[4]   Ventricular remodeling in heart failure: A credible surrogate endpoint [J].
Konstam, MA ;
Udelson, JE ;
Anand, IS ;
Cohn, JN .
JOURNAL OF CARDIAC FAILURE, 2003, 9 (05) :350-353
[5]  
Lehmann A, 2004, MED SCI MONITOR, V10, pMT89
[6]   Pharmacokinetics and pharmacodynamics of intravenous inotropic agents [J].
Lehtonen, LA ;
Antila, S ;
Pentikäinen, PJ .
CLINICAL PHARMACOKINETICS, 2004, 43 (03) :187-203
[7]   Drug therapy in chronic heart failure [J].
McKenzie, DB ;
Cowley, AJ .
POSTGRADUATE MEDICAL JOURNAL, 2003, 79 (937) :634-642
[8]   Predictors of inotrope use during separation from cardiopulmonary bypass [J].
McKinlay, KH ;
Schinderle, DB ;
Swaminathan, M ;
Podgoreanu, MV ;
Milano, CA ;
Messier, RH ;
El-Moalem, H ;
Newman, MF ;
Clements, FM ;
Mathew, JP .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2004, 18 (04) :404-408
[9]   Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anaesthesia record-keeping system [J].
Müller, M ;
Junger, A ;
Bräu, M ;
Kwapisz, MM ;
Schindler, E ;
Akintürk, H ;
Benson, M ;
Hempelmann, G .
BRITISH JOURNAL OF ANAESTHESIA, 2002, 89 (03) :398-404
[10]   Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial [J].
Nijhawan, N ;
Nicolosi, AC ;
Montgomery, MW ;
Aggarwal, A ;
Pagel, PS ;
Warltier, DC .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 34 (02) :219-228